@article {10482, title = {Circulating osteoprotegerin is associated with chronic kidney disease in hypertensive patients.}, journal = {BMC Nephrol}, volume = {18}, year = {2017}, month = {2017 Jul 06}, pages = {219}, abstract = {

BACKGROUND: Osteoprotegerin (OPG) is a glycoprotein that plays an important regulatory role in the skeletal, vascular, and immune system. It has been shown that OPG predicts chronic kidney disease (CKD) in diabetic patients. We hypothesized that OPG could be a risk marker of CKD development also in non-diabetic hypertensive patients.

METHODS: A case-control study was carried out to measure circulating OPG levels in 42 hypertensive patients with CKD and in 141 hypertensive patients without CKD. A potential relationship between OPG and the presence of CKD was investigated and a receiver-operating characteristic (ROC) curve was designed thereafter to identify a cut-off value of OPG that best explained the presence of CKD. Secondly, to evaluate whether OPG increase could affect the kidney, 18 C57BL/6J mice were randomized to be treated with saline or recombinant OPG every 3~weeks for 12~weeks.

RESULTS: Circulating OPG levels were significantly higher in hypertensive patients with CKD, and there was a significant inverse association between OPG and renal function, that was independent from other variables. ROC analysis showed that OPG levels had a high statistically predictive value on CKD in hypertensive patients, which was greater than that of hypertension. The OPG best cut-off value associated with CKD was 1109.19~ng/L. In the experimental study, OPG delivery significantly increased the gene expression of pro-inflammatory and pro-fibrotic mediators, as well as the glomerular nitrosylation of proteins.

CONCLUSIONS: This study shows that OPG is associated with CKD in hypertensive patients, where it might have a higher predictive value than that of hypertension for CKD development. Secondly, we found that OPG delivery significantly increased the expression of molecular pathways involved in kidney damage. Further longitudinal studies are needed not only to evaluate whether OPG predicts CKD development but also to clarify whether OPG should be considered a risk factor for CKD.

}, keywords = {Aged, Animals, Biomarkers, Case-Control Studies, Female, Follow-Up Studies, Humans, Hypertension, Male, Mice, Mice, Inbred C57BL, Middle Aged, Osteoprotegerin, Random Allocation, Renal Insufficiency, Chronic}, issn = {1471-2369}, doi = {10.1186/s12882-017-0625-3}, author = {Bernardi, Stella and Toffoli, Barbara and Bossi, Fleur and Candido, Riccardo and Stenner, Elisabetta and Carretta, Renzo and Barbone, Fabio and Fabris, Bruno} } @article {10558, title = {CYP3A genes and the association between prenatal methylmercury exposure and neurodevelopment.}, journal = {Environ Int}, volume = {105}, year = {2017}, month = {2017 08}, pages = {34-42}, abstract = {

BACKGROUND: Results on the association between prenatal exposure to methylmercury (MeHg) and child neuropsychological development are heterogeneous. Underlying genetic differences across study populations could contribute to this varied response to MeHg. Studies in Drosophila have identified the cytochrome p450 3A (CYP3A) family as candidate MeHg susceptibility genes.

OBJECTIVES: We evaluated whether genetic variation in CYP3A genes influences the association between prenatal exposure to MeHg and child neuropsychological development.

METHODS: The study population included 2639 children from three birth cohort studies: two subcohorts in Seychelles (SCDS) (n=1160, 20 and 30months of age, studied during the years 2001-2012), two subcohorts from Spain (INMA) (n=625, 14months of age, 2003-2009), and two subcohorts from Italy and Greece (PHIME) (n=854, 18months of age, 2006-2011). Total mercury, as a surrogate of MeHg, was analyzed in maternal hair and/or cord blood samples. Neuropsychological development was evaluated using Bayley Scales of Infant Development (BSID). Three functional polymorphisms in the CYP3A family were analyzed: rs2257401 (CYP3A7), rs776746 (CYP3A5), and rs2740574 (CYP3A4).

RESULTS: There was no association between CYP3A polymorphisms and cord mercury concentrations. The scores for the BSID mental scale improved with increasing cord blood mercury concentrations for carriers of the most active alleles (β[95\% CI]:=2.9[1.53,4.27] for CYP3A7 rs2257401 GG+GC, 2.51[1.04,3.98] for CYP3A5 rs776746 AA+AG and 2.31[0.12,4.50] for CYP3A4 rs2740574 GG+AG). This association was near the null for CYP3A7 CC, CYP3A5 GG and CYP3A4 AA genotypes. The interaction between the CYP3A genes and total mercury was significant (p<0.05) in European cohorts only.

CONCLUSIONS: Our results suggest that the polymorphisms in CYP3A genes may modify the response to dietary MeHg exposure during early life development.

}, keywords = {Adult, Child Development, Child, Preschool, Cohort Studies, Cytochrome P-450 CYP3A, Female, Fetal Blood, Genotype, Greece, Humans, Infant, Italy, Male, Mercury, Methylmercury Compounds, Neurodevelopmental Disorders, Neuropsychological Tests, Polymorphism, Genetic, Pregnancy, Prenatal Exposure Delayed Effects, Seychelles, Spain}, issn = {1873-6750}, doi = {10.1016/j.envint.2017.04.013}, author = {Llop, Sabrina and Tran, Van and Ballester, Ferran and Barbone, Fabio and Sofianou-Katsoulis, Aikaterini and Sunyer, Jordi and Engstr{\"o}m, Karin and Alhamdow, Ayman and Love, Tanzy M and Watson, Gene E and Bustamante, Mariona and Murcia, Mario and I{\~n}iguez, Carmen and Shamlaye, Conrad F and Rosolen, Valentina and Mariuz, Marika and Horvat, Milena and Tratnik, Janja S and Mazej, Darja and van Wijngaarden, Edwin and Davidson, Philip W and Myers, Gary J and Rand, Matthew D and Broberg, Karin} }